Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients
Abstract Background Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-04-01
|
| Series: | Journal of Cachexia, Sarcopenia and Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jcsm.12251 |
| _version_ | 1827280415999655936 |
|---|---|
| author | Erin E. Talbert Heather L. Lewis Matthew R. Farren Mitchell L. Ramsey Jeffery M. Chakedis Priyani Rajasekera Ericka Haverick Angela Sarna Mark Bloomston Timothy M. Pawlik Teresa A. Zimmers Gregory B. Lesinski Phil A. Hart Mary E. Dillhoff Carl R. Schmidt Denis C. Guttridge |
| author_facet | Erin E. Talbert Heather L. Lewis Matthew R. Farren Mitchell L. Ramsey Jeffery M. Chakedis Priyani Rajasekera Ericka Haverick Angela Sarna Mark Bloomston Timothy M. Pawlik Teresa A. Zimmers Gregory B. Lesinski Phil A. Hart Mary E. Dillhoff Carl R. Schmidt Denis C. Guttridge |
| author_sort | Erin E. Talbert |
| collection | DOAJ |
| description | Abstract Background Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer‐induced cachexia in patients with earlier stages of disease. Methods A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high‐sensitivity multiplex was used for increased sensitivity for nine cytokines. Results Resectable pancreatic cancer patients with cachexia had low levels of canonical pro‐inflammatory cytokines including interleukin‐6 (IL‐6), interleukin‐1β (IL‐1β), interferon‐γ (IFN‐γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein‐1 (MCP‐1) was increased in treatment‐naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) were found to be decreased in the same cohort of treatment‐naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment‐naïve patients have higher levels of MCP‐1, suggesting that MCP‐1 may be useful as a biomarker of cancer cachexia. |
| first_indexed | 2024-04-24T08:40:49Z |
| format | Article |
| id | doaj.art-320df16659484be68f873257a408f01b |
| institution | Directory Open Access Journal |
| issn | 2190-5991 2190-6009 |
| language | English |
| last_indexed | 2024-04-24T08:40:49Z |
| publishDate | 2018-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Cachexia, Sarcopenia and Muscle |
| spelling | doaj.art-320df16659484be68f873257a408f01b2024-04-16T16:11:14ZengWileyJournal of Cachexia, Sarcopenia and Muscle2190-59912190-60092018-04-019235836810.1002/jcsm.12251Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patientsErin E. Talbert0Heather L. Lewis1Matthew R. Farren2Mitchell L. Ramsey3Jeffery M. Chakedis4Priyani Rajasekera5Ericka Haverick6Angela Sarna7Mark Bloomston8Timothy M. Pawlik9Teresa A. Zimmers10Gregory B. Lesinski11Phil A. Hart12Mary E. Dillhoff13Carl R. Schmidt14Denis C. Guttridge15Arthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USADepartment of Hematology and Medical Oncology The Winship Cancer Institute of Emory University Atlanta GA 30322 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USA21st Century Oncology, Inc. Fort Myers FL 33966 USADepartment of Surgery, Division of Surgical Oncology The Ohio State University Columbus OH 43210 USADepartment of Surgery Indiana University School of Medicine Indianapolis IN 46202 USADepartment of Hematology and Medical Oncology The Winship Cancer Institute of Emory University Atlanta GA 30322 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAArthur G. James Comprehensive Cancer Center Cancer Cachexia Program The Ohio State University Columbus OH 43210 USAAbstract Background Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced disease and thus may be associated with disease progression rather than directly with the cachexia syndrome. Thus, we sought to assess potential biomarkers of cancer‐induced cachexia in patients with earlier stages of disease. Methods A custom multiplex array was used to measure circulating levels of 25 soluble factors from 70 pancreatic cancer patients undergoing attempted tumour resections. A high‐sensitivity multiplex was used for increased sensitivity for nine cytokines. Results Resectable pancreatic cancer patients with cachexia had low levels of canonical pro‐inflammatory cytokines including interleukin‐6 (IL‐6), interleukin‐1β (IL‐1β), interferon‐γ (IFN‐γ), and tumour necrosis factor (TNF). Even in our more sensitive analysis, these cytokines were not associated with cancer cachexia. Of the 25 circulating factors tested, only monocyte chemoattractant protein‐1 (MCP‐1) was increased in treatment‐naïve cachectic patients compared with weight stable patients and identified as a potential biomarker for cancer cachexia. Although circulating levels of leptin and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) were found to be decreased in the same cohort of treatment‐naïve cachectic patients, these factors were closely associated with body mass index, limiting their utility as cancer cachexia biomarkers. Conclusions Unlike in advanced disease, it is possible that cachexia in patients with resectable pancreatic cancer is not associated with high levels of classical markers of systemic inflammation. However, cachectic, treatment‐naïve patients have higher levels of MCP‐1, suggesting that MCP‐1 may be useful as a biomarker of cancer cachexia.https://doi.org/10.1002/jcsm.12251WastingWeight lossBiomarker |
| spellingShingle | Erin E. Talbert Heather L. Lewis Matthew R. Farren Mitchell L. Ramsey Jeffery M. Chakedis Priyani Rajasekera Ericka Haverick Angela Sarna Mark Bloomston Timothy M. Pawlik Teresa A. Zimmers Gregory B. Lesinski Phil A. Hart Mary E. Dillhoff Carl R. Schmidt Denis C. Guttridge Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients Journal of Cachexia, Sarcopenia and Muscle Wasting Weight loss Biomarker |
| title | Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients |
| title_full | Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients |
| title_fullStr | Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients |
| title_full_unstemmed | Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients |
| title_short | Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients |
| title_sort | circulating monocyte chemoattractant protein 1 mcp 1 is associated with cachexia in treatment naive pancreatic cancer patients |
| topic | Wasting Weight loss Biomarker |
| url | https://doi.org/10.1002/jcsm.12251 |
| work_keys_str_mv | AT erinetalbert circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT heatherllewis circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT matthewrfarren circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT mitchelllramsey circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT jefferymchakedis circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT priyanirajasekera circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT erickahaverick circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT angelasarna circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT markbloomston circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT timothympawlik circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT teresaazimmers circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT gregoryblesinski circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT philahart circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT maryedillhoff circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT carlrschmidt circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients AT deniscguttridge circulatingmonocytechemoattractantprotein1mcp1isassociatedwithcachexiaintreatmentnaivepancreaticcancerpatients |